2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
In our exclusive interview, Marc J. Braunstein, MD, PhD, provides perspective on data in the upfront and relapsed/refractory settings regarding the use of triplet and quadruplet regimens, novel agents, and cellular therapies.
Welcome to a very special edition of OncLive® On Air! I’m your host today, Jessica Hergert.
OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
Today, we had the pleasure of speaking with Marc J. Braunstein, MD, PhD, to discuss some of the most noteworthy data in multiple myeloma that were presented during the 2020 ASCO Virtual Scientific Program.
In our exclusive interview, Dr. Braunstein, assistant professor in the Department of Medicine at NYU Long Island School of Medicine; course co-director of the Hematology-Oncology System and co-director of the Autologous Stem Cell Transplant Program, at NYU Winthrop Hospital of NYU Langone Health’s Perlmutter Cancer Center, provided perspective on data in the up-front and relapsed/refractory settings regarding the use of triplet and quadruplet regimens, novel agents, and cellular therapies.